Dr. Falk Pharma GmbH is advancing norUDCA as a potential treatment for NASH, a condition with significant unmet medical need and a growing patient population. The Phase 2b trial aims to establish the efficacy and safety of norUDCA compared to placebo, with two dosing regimens (1000 mg/d and 1500 mg/d). If successful, this could position norUDCA favorably in a competitive landscape that includes other emerging therapies for NASH, such as obeticholic acid and elafibranor. The trial's outcomes may influence future partnerships or acquisition interest, particularly given the increasing focus on liver diseases in the biopharmaceutical sector.